November 7th 2024

Publication in Antiviral Research: Combining of Remdesivir, Molnupiravir and Ribavirin inhibits coronavirus replication

Publication in Antiviral Research: Combining of Remdesivir, Molnupiravir and Ribavirin inhibits coronavirus replication

Further to CARE’S SARS-CoV-2 research, CARE partner KU Leuven has explored the inhibitory effect of a combination of 3 broad-spectrum antiviral nucleosides on the replication of coronaviruses as demonstrated through experiments with infected primary human airway epithelial cell (HAEC) cultures and subsequently through testing in SARS-CoV-2 infected hamsters in a prophylactic setup. This work indicates that co-administration of approved drugs for the treatment of coronavirus and other virus infections should be further explored.

To learn more, click here: The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model – ScienceDirect